Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Glycine Trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1h-indazol-1-yl)phenyl)amino)cyclohexyl Ester
2. Pf 04929113
3. Pf-04929113
4. Pf-4929113
5. Pf04929113
6. Snx-5422 Mesylate
1. 908115-27-5
2. Pf-04929113
3. Snx 5422
4. Pf-4929113
5. Pf 04929113
6. Snx5422
7. Pf04929113
8. Pf-04929113 (snx-5422)
9. Pf-04929113 Free Base
10. Bf52j69q8t
11. 908115-27-5 (free Base)
12. (1r,4r)-4-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1h-indazol-1-yl)phenyl)amino)cyclohexyl Glycinate
13. [4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]anilino]cyclohexyl] 2-aminoacetate
14. Glycine, Trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1h-indazol-1-yl)phenyl)amino)cyclohexyl Ester
15. 908116-67-6
16. Glycine, 4-[[2-(aminocarbonyl)-5-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1h-indazol-1-yl]phenyl]amino]cyclohexyl Ester
17. Unii-bf52j69q8t
18. Mls006011083
19. Schembl1220790
20. Schembl1220791
21. Chembl1195136
22. Schembl15604989
23. Dtxsid50238270
24. Snx 5422 [who-dd]
25. Bcpp000065
26. Hms3656b09
27. Bcp02427
28. Ex-a2343
29. Bdbm50514916
30. Nsc768509
31. S2656
32. Zinc95616595
33. Akos027276395
34. Zinc100071931
35. Zinc252517142
36. Ccg-269865
37. Cs-0272
38. Db06070
39. Nsc-768509
40. Sb16643
41. Ncgc00346640-01
42. Ncgc00346640-04
43. Ncgc00386184-02
44. Ac-36033
45. Hy-10213
46. Smr004702871
47. Sw220153-1
48. Snx-5422(pf04929113)
49. Pf-0492911 - Snx-5422
50. Pf-04929113; Snx-5422
51. A857805
52. J-521414
53. Brd-k73197500-066-01-7
54. Q27274626
55. (1r,4r)-4-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)phenylamino)cyclohexyl 2-aminoacetate
56. Glycine Trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1h-indazol-1-yl)phenyl)amino)cycloh Exyl Ester
57. Glycine Trans-4-[[2-(aminocarbonyl)-5-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1h-indazol-1-yl]phenyl]amino]cyclohexyl Ester;pf-04929113
58. Trans-4-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1h-indazol-1-yl)phenyl)amino)cyclohexyl 2-aminoacetate
| Molecular Weight | 521.5 g/mol |
|---|---|
| Molecular Formula | C25H30F3N5O4 |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | 521.22498894 g/mol |
| Monoisotopic Mass | 521.22498894 g/mol |
| Topological Polar Surface Area | 142 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 877 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified).
SNX-5422 is under development by Serenex. It is orally administered (pill form). Once in the body, SNX-5422 is converted to SNX-2122; that is, SNX-5422 is a prodrug of SNX-2112, which is the active form.
SNX-5422 is a direct, potent inhibitor of Hsp90 across a broad range of human cancer cell lines and causes degradation of important Hsp90 client proteins including HER2, AKT and ERK.
ABOUT THIS PAGE
36
PharmaCompass offers a list of Snx-5422 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Snx-5422 manufacturer or Snx-5422 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Snx-5422 manufacturer or Snx-5422 supplier.
PharmaCompass also assists you with knowing the Snx-5422 API Price utilized in the formulation of products. Snx-5422 API Price is not always fixed or binding as the Snx-5422 Price is obtained through a variety of data sources. The Snx-5422 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A SNX-5422(PF04929113) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of SNX-5422(PF04929113), including repackagers and relabelers. The FDA regulates SNX-5422(PF04929113) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. SNX-5422(PF04929113) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A SNX-5422(PF04929113) supplier is an individual or a company that provides SNX-5422(PF04929113) active pharmaceutical ingredient (API) or SNX-5422(PF04929113) finished formulations upon request. The SNX-5422(PF04929113) suppliers may include SNX-5422(PF04929113) API manufacturers, exporters, distributors and traders.
SNX-5422(PF04929113) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of SNX-5422(PF04929113) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right SNX-5422(PF04929113) GMP manufacturer or SNX-5422(PF04929113) GMP API supplier for your needs.
A SNX-5422(PF04929113) CoA (Certificate of Analysis) is a formal document that attests to SNX-5422(PF04929113)'s compliance with SNX-5422(PF04929113) specifications and serves as a tool for batch-level quality control.
SNX-5422(PF04929113) CoA mostly includes findings from lab analyses of a specific batch. For each SNX-5422(PF04929113) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
SNX-5422(PF04929113) may be tested according to a variety of international standards, such as European Pharmacopoeia (SNX-5422(PF04929113) EP), SNX-5422(PF04929113) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (SNX-5422(PF04929113) USP).
